Postprandial glycemic control conditions in relation to urinary n-acetyl-β-d-glucosaminidase in patients with type 2 diabetes mellitus without low glomerular filtration rate

Diabetes Technology and Therapeutics

Volumn 16, Issue 1, 2014, Pages 41-47

  Ouchi, Motoshi ^a   Oba, Kenzo ^a,b   Motoyama, Masayuki ^a,b   Tsunoda, Misako ^a   Yamashita, Hidetoshi ^a   Aoyama, Junya ^a   Saigusa, Taro ^a   Ishii, Kazuhito ^a   Yano, Hiroyuki ^a   Hashimoto, Masao ^a   Sekimizu, Ken Ichi ^a   Suzuki, Tatsuya ^a   Nakano, Hiroshi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Department of Internal Medicine Oarai Coast Core Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; N ACETYL BETA GLUCOSAMINIDASE; ORAL ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; VERY ELDERLY; YOUNG ADULT;

ACETYLGLUCOSAMINIDASE; ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; JAPAN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 84891864231     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0155     Document Type: Article

References (33)

1. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-621.
2. Tominaga M, Igarashi K, Eguchi H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22: 920-924. (Pubitemid 29241045)
3. Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M: Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: Implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24:2023-2029. (Pubitemid 33716515)
4. American Diabetes Association: Postprandial blood glucose. Diabetes Care 2001;24:775-778.
5. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S: 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006;29:1214-1219. (Pubitemid 44125912)
6. McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, Sarno MJ: Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: A U.S. trial of the GlycoMark assay. Diabetes Care 2004;27:1859-1865. (Pubitemid 38989223)
7. Yamanouchi T, Inoue T, Ogata E, Kashiwabara A, Ogata N, Sekino N, Yoshimura T, Ichiyanagi K, Kawasaki T: Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. Clin Sci (Lond) 2001;101:227-233. (Pubitemid 32835519)
8. Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, Tominaga Y: Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in noninsulin-treated NIDDM patients. Diabetes Care 1998;21:256-260. (Pubitemid 28079434)
9. Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, Krolewski AS, Bonventre JV: Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-b-d-glucosaminidase. Kidney Int 2011;79:464-470.
10. Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, van Veldhuisen DJ, Montagna L, Cosmi F, Tognoni G, Tavazzi L, Latini R: Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011;32:2705-2712.
11. Whiting PH, Nicholls AJ, Catto GRD, Edward N, Engeset J: Patterns of N-acetyl-b-d-glucosaminidase excretion after renal transplantation. Clin Chim Acta 1980;108:1-7. (Pubitemid 11225056)
12. Diener U, Knoll E, Langer B, Rautenstrauch H, Ratge D, Wisser H: Urinary excretion of N-acetyl-b-d-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum. Clin Chim Acta 1981;112:149-157. (Pubitemid 11156250)
13. Dance N, Price RG, Cattell WR, Lansdell J, Richards B: The excretion of N-acetyl-b-glucosaminidase and b-galactosidase by patients with renal disease. Clin Chim Acta 1970;27: 87-92.
14. Gibey R, Dupond JL, Alber D, Leconte des Floris R, Henry JC: Predictive value of urinary N-acetyl-beta-d-glucosaminidase (NAG), alanine-aminopeptidase (AAP) and beta-2-microglobin (b2M) in evaluating nephrotoxicity of gentamicin. Clin Chim Acta 1981;116:25-34. (Pubitemid 11060000)
15. Kern EF, Erhard P, Sun W, Genuth S, Weiss MF: Early urinary markers of diabetic kidney disease: A nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis 2010;55:824-834.
16. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
17. Yamanouchi T, Kawasaki T, Yoshimura T, Inoue T, Koshibu E, Ogata N, Funato H, Akaoka I, Miyashita H: Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. Diabetes Care 1998;21: 619-624. (Pubitemid 28172945)
18. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H; Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society: International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 2012;3:8-10.
19. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.
20. Yoshioka K, Azukari K, Yoshida T, Kondo M: Rapid improvement of serum 1,5-anhydroglucitol concentrations after administration of a-glucosidase inhibitor. Diabetes Care 1997;20:462. (Pubitemid 27098243)
21. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB: Serum 1,5-anhydroglucitol (GlycoMark): A short-term glycemic marker. Diabetes Technol Ther 2003;5:355-363. (Pubitemid 36676309)
22. Fukumura Y, Tajima S, Oshitani S, Ushijima Y, Kobayashi I, Hara F, Yamamoto S, Yabuuchi M: Fully enzymatic method for detecting 1,5-anhydro-d-glucitol in serum. Clin Chem 1994;40:2013-2016. (Pubitemid 24346165)
23. Ouchi M, Oba K, Yamashita H, Okazaki M, Tsunoda M, Ohara M, Sekimizu K, Watanabe K, Suzuki T, Nakano H: Effects of sex and age on serum 1,5-anhydroglucitol in nondiabetic subjects. Exp Clin Endocrinol Diabetes 2012;120:288-295.
24. Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T: Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: An 11-year populationbased cohort study in Japan, the Suita study. Atherosclerosis 2011;216:477-483.
25. Magri CJ, Fava S: The role of tubular injury in diabetic nephropathy. Eur J Intern Med 2009;20:551-555.
26. Phillips A, Janssen U, Floege J: Progression of diabetic nephropathy, insights from cell culture studies and animal models. Kidney Blood Press Res 1999;22:81-97. (Pubitemid 29243450)
27. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: More than aftermath of glomerular injury Kidney Int 1999;56:1627-1637. (Pubitemid 29518163)
28. Alderman MH, Melcher L, Drayer DE, Reidenberg MM: Increased excretion of urinary N-acetyl-b-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. N Engl J Med 1983;309:1213-1217. (Pubitemid 14240900)
29. Nauta FL, Boertien WE, Bakker SJ, van Goor H, van Oeveren W, de Jong PE, Bilo H, Gansevoort RT: Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 2011;34:975-981.
30. Fu WJ, Xiong SL, Fang YG, Wen S, Chen ML, Deng RT, Zheng L, Wang SB, Pen LF, Wang Q: Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: A cross-sectional study. Endocrine 2012;41:82-88.
31. Ouchi M, Suzuki T, Hashimoto M, Motoyama M, Ohara M, Suzuki K, Igari Y,Watanabe K, Nakano H, Oba K: Urinary Nacetyl-b-d-glucosaminidase levels are positively correlated with 2-hour plasma glucose levels during oral glucose tolerance testing in prediabetes. J Clin Lab Anal 2012;26:473-480.
32. Ellis EN, Brouhard BH, Lagrone L, Travis LB: Urinary excretion of N-acetyl-beta-d-glucosaminidase in children with type 1 diabetes mellitus. Diabetes Care 1983;6:251-255. (Pubitemid 13096156)
33. Oba K, Hirai M, Ajiro Y, Okazaki K, Sato S, Sasai K, Suzuki T, Nakano H, Metori S: Effect of age on urinary excretion of N-acetyl-b-d-glucosaminidase. J Nippon Med Sch 1999; 66:33-36.